LES APPELS A PROPOSITIONS DU 6ème PCRDT EN 2005

Identifiant de l'appel	Ouverture	Clôture	Budget	Programme de travail	Guides du proposant
1 Sciences de la vie (LSH)					
FP6-2005-LIFESCIHEALTH-6	Mai 2005	Nov. 2005	368 M€	prog. de travail	IP ; NOE ; STREP ; CA ; SSA
FP6-2005-LIFESCIHEALTH-_SME	Mai 2005	?	179 M€	prog. de travail	STREP
2 Technologies pour la société de l'information (IST)					
FP6-2004-IST-4	25/11/2004	22/03/2005	1 120 M€	prog. de travail	IP ; NOE ; STREP ; CA ; SSA
FP6-2002-IST-C	17/12/2002	20/09/2005	60 M€	prog. de travail	STREP ; SSA ; CA
FP6-2005-IST-5	17/05/2005	21/09/2005	638 M€	prog. de travail	IP ; NOE ; STREP ; CA ; SSA
3 Nanotechnologies, Matériaux, Procédés de production (NMP)					
FP6-2004-NMP-NI-4	08/12/2004	17/03/2005 (1ère ét)	150 M€	Prog.de travail	IP
FP6-2004-NMP-TI-4	08/12/2004	15/09/2005	120 M€	Prog.de travail	STREP, CA, SSA
FP6-2004-NMP-SME-4	08/12/2004	17/03/2005 (1ère ét)	100 M€	Prog.de travail	IP-PME
4 Aéronautique et Espace (AEROSPACE)					
FP6-2005-AERO-1	12/03/2005	13/07/2005	230 M€	Version provisoire	IP ; NOE ; STREP ; CA
FP6-2005-SPACE-1	12/03/2005	13/07/2005	50 M€	Version provisoire	IP ; STREP ; CA ; SSA
FP6-2005-TREN-4_aero	Juin 2005	Déc 2005	? M€	n.d	n.d
5 Qualité et sûreté alimentaire (FOOD)					
FP6-2004-Food-3-C	24/07/2004	07/09/2005	5 M€	prog. de travail	SSA
FP6-2005-Food-4	Juin 2005	10/2005 (IP/NOE) 01/2006 (STREP /CA /SSA)	130 M€	n.d	IP ; NOE ; STREP ; CA ; SSA
6. Développement durable, changement global et écosystème (SUSTDEV)					
6.1 Systèmes énergétiques durables					
FP6-2005-TREN-4_energy	Juin 2005	Déc 2005	? M€	n.d	n.d
6.2 Transports de surface durable					
FP6-2002-Transport-2 Corr. du 29/01/2003 Corr. du 02/04/2003	17/12/2002	Open call	5 M€	prog. de travail	SSA
FP6-2005-Transport-4	12/03/2005	01/09/2005	150 M€	n.d	IP ; NOE ; STREP ; CA
FP6-2005-TREN-4_transp	Juin 2005	Déc 2005	? M€	n.d	n.d
6.3 Changement global et écosystème					
FP6-2005-GLOBAL-4	Juin 2005	Nov. 2005	210 M€	n.d	IP ; NOE ; STREP ; CA ; SSA
7 Citoyens et gouvernance dans une société de la connaissance					
FP6-2004-CITIZENS-4	08/12/2004	13/04/2005	60 M€	prog. de travail	IP ; NOE
FP6-2004-CITIZENS-5	08/12/2004	13/04/2005	52 M€	prog. de travail	STREP ; CA
FP6-2004-CITIZENS-6	08/12/2004	13/04/2005	4 M€	prog. de travail	SSA

8 Soutien aux politiques de recherche					
FP6-2004-SSP-4	30/10/2004	01/02/2005	77.8 M€	prog. de travail	STREP ; CA ; SSA ; Detailed background document on SSP - Fourth call
9 Nouvelles technologies émergentes (NEST)					
FP6-2004-NEST-C-1	10/12/2004	13/04/2005	28 M€	prog. de travail	STREP
FP6-2004-NEST-C-2	10/12/2004	13/04/2005	2 M€	prog. de travail	SSA
FP6-2004-NEST-path	10/12/2004	13/04/2005	35 M€	prog. de travail	STREP ; SSA ; CA
10 Activités PME					
FP6-2004-SME-COOP	15/12/2004	14/09/2005	75 M€	prog. de travail (précédente version)	CRAFT (précédente version)
FP6-2004-SME-COLL	15/12/2004	26/05/2005 (1" ét)	65 M€	prog. de travail (précédente version)	COLL(précédente version)
11 Coopération internationale					
FP6-2004-INCO-DEV-3	17/12/2004	13/09/2005	60 M€	prog. de travail	CA ; STREP
FP6-2004-INCO-MPC-3	17/12/2004	13/09/2005	10 M€	prog. de travail	CA ; STREP
FP6-2004-INCO-WBC/SSA-3	17/12/2004	07/03/2005	3 M€	prog. de travail	SSA
FP6-2002-INCO-DEV/SSA-1	17/12/2002	07/03/2005 07/09/2005 06/03/2006	1.9 M€ (2004)	prog. de travail	SSA
FP6-2002-INCO-MPC/SSA-2	17/12/2002	07/03/2005 07/09/2005 06/03/2006	0.9 M€ (2004)	prog. de travail	SSA
FP6-2002-INCO-WBC/SSA-3	17/12/2002	07/03/2005 07/09/2005 06/03/2006	0.9 M€ (2004)	prog. de travail	SSA
FP6-2002-INCO-Russia+NIS/SSA-4	17/12/2002	07/03/2005 07/09/2005 06/03/2006	0.9 M€ (2004)	prog. de travail	SSA
FP6-2002-INCO-COMultilatRTD/SSA-5	17/12/2002	07/03/2005 07/09/2005 06/03/2006	1.5 M€ (2004)	prog. de travail	SSA
12 Coordination des activités de recherche					
FP6-2002-ERA-NET-1-CA-SSA	17/12/2002	02/03/2005 04/10/2005	48 M€ et 18.6 M€ en 2005	prog. de travail	CA
13 Développement cohérent des politiques d'innovation et de recherche					
FP6-2004-KNOW-REG-2	31/12/2004	19/05/2005	8.95 M€	prog. de travail	CA
14 Recherche et innovation					
FP6-2004-INNOV-5	19/10/2004	10/02/2005	22 M€	prog. de travail	CA ; SSA
FP6-2004-INNOV-6	26/10/2004	27/01/2005	20 M€	prog. de travail	CA ; SSA

15	Ressources Humaines et Mobilité (Actions Marie Curie)				
FP6-2005-Mobility-4	19/01/2005	18/05/2005	12.25 M€	prog. de travail	Marie Curie Conferences and Training Courses (SCF)
FP6-2004-Mobility-3	15/12/2004	18/05/2005	45 M€	prog. de travail Guide évaluateur	Marie Curie Host Fellowships for the Transfer of Knowledge (TOK)
FP6-2004-Mobility-5	15/10/2004	16/02/2005	65 M€	prog. de travail	Intra European Fellowships
FP6-2004-Mobility-8	15/10/2004	16/02/2005	40 M€	prog. de travail	Excellence Grants (EXT)
FP6-2004-Mobility-9	15/10/2004	16/02/2005	250 000 €	prog. de travail	Excellence Awards (EXA)
FP6-2004-Mobility-10	15/10/2004	16/02/2005	8 M€	prog. de travail	Chairs (EXC)
FP6-2004-Mobility-11	15/10/2004	19/04/2005 19/07/2005 19/10/2005 19/01/2006 19/04/2006 19/07/2006 11/10/2006	10 M€	prog. de travail	European Reintegration Grants (ERG)
FP6-2004-Mobility-12	15/10/2004	19/04/2005 19/07/2005 19/10/2005 19/01/2006 19/04/2006 19/07/2006	10 M€	prog. de travail	International Re-integration Grants (IRG)
FP6-2004-Mobility-1	02/09/2004	28/04/2005	45 M€	prog. de travail	Research Training Network
16	Infrastructures de Recherche				
FP6-2004-infrastructure-6	15/12/2004	17/03/2005	25 M€	prog. de travail	CA ; SSA; I3
FP6-2004-infrastructure-5	04/11/2004	03/03/2005	145 M€	prog. de travail	CA ; SSA (transnational access) ; SSA (accompagning measures); I3
17	Science et Société				
FP6-2004-Science-and-Society-12	15/12/2004	10/05/2005	1,25 M€	prog. de travail	SSA
FP6-2005-Science-and-Society-13	09/02/2004	24/05/2005	2.2 M€	prog. de travail	SSA ; CA
18	EURATOM				
Euratom Call Open amendement du 01/12/2004	17/12/2003	12/04/2005 11/04/2005 11/10/2005 11/04/2006	1.5 M€	prog. de travail	training fellowship&grants third countries ; SSA ; Transnational access
FP6-2005-EURATOM	Avril 2005	Oct. 2005	52 M€		IP ; NOE ; I3 ; STREP ; CA

Priorité 1 – Sciences du vivant, génomique et biotechnologie pour la santé

1	Sciences de la vie (LSH)			
FP6-2005-LIFESCIHEALTH-6	Mai 2005	Nov. 2005	368 M€	IP ; NOE ; STREP ; CA ; SSA
FP6-2005-LIFESCIHEALTH-_SME	Mai 2005	?	179 M€	STREP-PME

Area	4th Call Indicative budget for traditional call (M €)	4th Call Indicative budget for SME call (M €)	4th Call Total Indicative Budget (M €)
i a) Fundamental knowledge and basic tools for functional genomics in all organisms	77	35	112
i b) Application of knowledge and technologies in the field of genomics and biotechnology for health	89	46	135
ii a) Application-orientated genomics approaches to medical knowledge and technologies	100	45	145
b) Combating cancer	49	25	74
c) Confronting the major communicable diseases linked to poverty	47	20	67
Strategic Specific Support Actions across thematic priority 1	6	0	6
Total (M €)	368	171	539

I. Advanced genomics and its applications for health

a) Fundamental knowledge and basic tools for functional genomics in all organisms

Gene expression and proteomics

- **LSH-*xxxxxx*:** A systems approach to understanding the regulation of gene transcription **– *IP***

Comparative genomics and population

- ***LSH-xxxxxx:*** *Functional genomics in Arabidopsis thaliana* **- *IP***
- **LSH-*xxxxxx*:** High throughput phenotyping tools and approaches for large scale functional genomics studies **– *NOE***
- **LSH-*xxxxxx*:** Population cohorts for molecular epidemiological studies in European populations **– *IP***

Multidisciplinary functional genomics approaches to basic biological processes

- **LSH-xxxxxx:** Functional genomics of autosomal aneuploid syndromes **– IP**
- **LSH-xxxxxx:** The biological role of small regulatory RNAs **- *IP***
- **LSH-xxxxxx:** Specific Support Actions (**SSA**s)
- **LSH-xxxxxx:** Proposals for Co-ordination Actions (**CA**) in functional genomics research will also be considered.

– **LSH-xxxxxx:** Proposals concerned with the development of tools and technologies for functional genomics (proteomics, gene expression, structural genomics, comparative genomics, population genetics, bioinformatics etc) will be eligible **SME-STREP**

b)Application of knowledge and technologies in the field of genomics and biotechnology for health

Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches

- **LSH-xxxxxx:** Marker profiling as a new tool for predictive toxicology **- *IP***
- **LSH-xxxxxx:** New tools to investigate ADME properties of drugs involving a carrier system **– *STREP***
- **LSH-xxxxx:** Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches **– *STREP***

Development of new diagnostics

- **LSH-xxxxxx:** High throughput molecular diagnostics for hereditary diseases **- *INTEGRATED PROJECT*.**
- **LSH-xxxxxx:** Development of innovative methods for diagnosis of nervous system disorders **– *STREP.***
- **LSH-xxxxxx:** Nanoparticles-based diagnostics **– *STREP.***
- **LSH-xxxxxx:** Development of new diagnostics **– *STREP dedicated to SMEs***

Development of new in vitro tests to replace animal experimentation

- **LSH-xxxxxx:** Predictive *in vitro* testing strategies for human exposure to chemicals **- *IP***
- **LSH-xxxxxx:** Workshop on business opportunities for *in vitro* pharmaceutical toxicology **– *SSA.***
- **LSH-xxxxxx:** Researchers and regulators meet manufacturers of toxicology test methods **– *SSA.***
- **LSH-xxxxxx:** Development of new in vitro tests to replace animal experimentation **– *STREP dedicated to SMEs.***

Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies.

- **LSH-xxxxxx:** Tissue engineering approaches to treating children with birth defects **- *IP***
- **LSH-xxxxxx:** Hepatitis C vaccine **- *IP***
- **LSH-xxxxxx:** Stem Cell Therapy for Stroke Patients **– *STREP***
- **LSH-xxxxxx:** Methodological research to underpin stem cell banking **- *STREP.***

- **LSH-xxxxxx:** Use of baculovirus as a vector in gene therapy (especially orientated towards small and medium sized companies) **– *STREP***

- **LSH-xxxxxx:** Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies **– *STREP dedicated to SMEs***

Innovative research in post-genomics, which has high potential for application

- **LSH-xxxx:** Application of post-genomics to xenotransplantation research **– *IP***
- **LSH-xxxxxx:** Post-genomic approaches exploiting aquatic molecular biodiversity for biomedical applications **- *IP***
- **LSH-xxxxxx:** Use of cell lines to define new bioassays for the identification of therapeutic bio-molecules (especially orientated towards small and medium sized companies) **- *STREP.***

– **LSH-xxxxxx:** Innovative research in post-genomics, which has high potential for application ***– STREP dedicated to SMEs***

II COMBATING MAJOR DISEASES

a) Applications-orientated genomic approaches to medical knowledge and technologies

General (overarching)

- **LSH-xxxxxx:** Genetic control of the pathogenesis of diseases based on iron metabolism **– *STREP.***

Combating, cardiovascular disease, diabetes and rare diseases

- **LSH-xxxxxx:** Genetic mapping and functional genomics of susceptibility to coronary artery disease **– *IP***
- **LSH-xxxxxx:** Hypertension and cardiovascular disease **– *NOE***

- **LSH-xxxxxx:** Molecular, genomic and applied genomic studies for the prevention of accelerated cardiovascular death in uraemia and end-stage renal disease - ***STREP*.**
- **LSH-xxxxxx:** Functional genomics and regulatory networks in lipid metabolism and their effects on the development of atherogenic vascular disease **-** ***STREP*.**
- **LSH-xxxxxx:** Gene-environment interaction on the incidence of type 2 diabetes **-** ***IP***
- **LSH-xxxxxx:** Molecular pathways underlying decreased beta cell mass in diabetes mellitus **-** ***STREP.***

- **LSH-xxxxxx:** Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies **- *NOE***
- **LSH-xxxxxx:** Rare disorders of protein folding – ***STREP.***
- **LSH-xxxxxx:** Rare diseases of mesoderm-derived structures **– *STREP*.**
- **LSH-xxx:** Research on cardiovascular and/or cerebrovascular disease with strong SME involvement **– *STREP dedicated to SMEs***
- **LSH-xxxxxx:** Development of preventive and therapeutic strategies for Type 1 diabetes with strong SME involvement **– *STREP dedicated to SMEs.***

– **LSH-xxxxxx:** Development of *in vitro* and/or animal models for rare diseases **– *STREP dedicated to SMEs***

Combating resistance to antibiotics and other drugs

- **LSH-xxxxxx:** Control of antimicrobial resistance in hospital acquired and other health care associated infections **– *IP***
- **LSH-xxxxxx:** Molecular ecology of antibiotic drug resistance **– *IP***
- **LSH-xxxxxx:** Workshop exploring novel opportunities towards the development of vaccines that will have a significant impact on the control of anti-bacterial resistance **- *SSA.***
- **LSH-xxxxxx:** Development of new diagnostic tests for the management and control of antimicrobial resistance **– *STREP dedicated to SMEs***

– **LSH-xxxxxx:** Development of novel principles for anti-microbial treatment ***– STREP dedicated to SMEs***

Studying the brain and combating diseases of the nervous system

- **LSH-xxxxxx:** Functional genomics and neurobiology of epilepsy **– *IP***
- **LSH-xxxxxx:** Neuroimaging: “Bridging genetics and neural function” **– *IP***
- **LSH-xxxxxx:** Cortical information processing **– *STREP.***
- **LSH-xxxxxx:** Schizophrenia: from genotype to phenotype **– *STREP.***

- **LSH-xxxxxx:** Initiative in neuroinformatics **– *SSA.***
- **LSH-xxxxxx:** Neuroscience-oriented new technologies **– *STREP dedicated to SMEs***
- **LSH-xxxxxx:** Characterisation and use of animal models for neurological and psychiatric diseases **– *STREP dedicated to SMEs***
- **LSH-xxxxxx:** Early markers and new targets for neurodegenerative diseases **– *STREP dedicated to SMEs***
- **LSH-xxxxxx:** Perinatal brain damage: early markers and neuroprotection **– *STREP dedicated to SMEs***

Studying human development and the ageing process

- **LSH-xxxxxx:** Integration of research in development and ageing **– *NOE***
- **LSH-xxxxxx:** Attracting researchers to ageing research **- *SSA***
- **LSH-xxxxxx:** Understanding the responsiveness of elderly people towards vaccination and infectious diseases **– *STREP dedicated to SMEs***

b. Combating cancer

- **LSH-xxxxxx:** Modulation of apoptosis in cancer prevention and therapy – ***IP***
- **LSH-xxxxxx:** Broadening the knowledge base on the molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity **– *IP***
- **LSH-xxxxxx:** Early diagnosis and novel therapies of childhood cancers **– *STREP*.**
- **LSH-xxxxxx:** Innovative research on palliative care in patients with advanced stages of cancer **– *STREP*.**

- **LSH-xxxxxx:** Role of chromosomal aberrations and epigenetic mechanisms in haematological cancers **– *STREP*.**
- **LSH-xxxxxx:** Identification and validation of biomarkers in molecular cancer epidemiology **– *STREP*.**
- **LSH-xxxxxx:** Exploring the patient's cancer stem cell as a novel therapeutic target **– *STREP***
- **LSH-xxxxxx:** Innovative technological approaches for cancer therapy **– *STREP dedicated to SMEs***
- **LSH-xxxxxx:** Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy **– *STREP dedicated to SMEs***

- **LSH-xxxxxx:** Improving resolution of current imaging devices relevant to cancer diagnosis and therapy **– *STREP dedicated to SMEs***
- ***LSH-xxxxxx:*** *Application of "molecular signatures" for the early diagnosis of cancer patients* **– *STREP dedicated to SMEs***

c. Confronting the major communicable diseases linked to poverty

- **LSH-xxxxxx:** HIV/AIDS Therapeutic Clinical trials network **- *NOE***
- **LSH-xxxxxx:** HIV/AIDS Vaccines /Microbicides Network ***NOE***
- **LSH-xxxxxx:** New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis **– *STREP***
- **LSH-xxxxxx:** Basic studies of undesirable immunological reactions and adverse effects of drugs and vaccines for PRD **– *STREP***

- **LSH-xxxxxx:** Integration and coordination of European clinical research on malaria and tuberculosis **- *SSA/CA***
- **LSH-xxxxxx:** Promotion of PRD research **- *SSA/CA***
- **LSH-xxxxxx:** European Network for vaccine development **- *SSA/CA***
- **LSH-xxxxxx:** Highly innovative interventions for poverty related diseases **– *STREP dedicated to SMEs***
- **LSH-xxxxxx:** Development of fast tests for diagnosis of poverty related diseases suitable for use in resource-poor settings **– *STREP dedicated to SMEs***

- **LSH-xxxxxx:** Innovative delivery mechanism for treatment and depot therapy in PRD ***– STREP dedicated to SMEs***
- **LSH-xxxxxx:** Improving participation of the private sector in PRD research ***– SSA dedicated to SMEs***

+ SSA Transversales

Priorité 2 Technologies pour la société de l'information (IST)

2	Technologies pour la société de l'information (IST)			
FP6-2004-IST-4	25/11/2004	22/03/2005	1 120 M€	IP ; NOE ; STREP ; CA ; SSA
FP6-2002-IST-C	17/12/2002	20/09/2005	60 M€	STREP ; SSA ; CA
FP6-2005-IST-5	17/05/2005	21/09/2005	638 M€	IP ; NOE ; STREP ; CA ; SSA

	Objectifs stratégiques 2005-2006	Instruments	NI/TI	Budget indicatif M€
2.5.1	Composants photoniques	IP, STREP, CA, SSA	65/35	47
2.5.2	Sous-systèmes à l'échelle micro/nanométrique	IP, STREP, CA, SSA	70/30	58
2.5.3	Systèmes enfouis	IP, NoE, STREP, SSA, CA	60/40	68
2.5.4	Technologies, systèmes et services avancés de calcul distribué	IP, STREP, SSA,CA	70/30	62

2.5.5	Logiciels et services	IP, NoE, STREP, SSA, CA	60/40	67
2.5.6	Bancs d'essai pour la mise en réseau de la recherche	IP, NoE, STREP,SSA, CA	65/35	18
2.5.7	Interfaces multimodales	IP, STREP	60/40	54
2.5.8	TIC pour les entreprises en réseau	IP, NoE, STREP, CA, SSA	55/45	46
2.5.9	Environnements de travail collaboratif	IP, STREP, SSA, CA	70/30	40
2.5.10	Accessibilité et conservation des ressources culturelles et scientifiques	IP, STREP, CA	40/60	36

2.5.11	eInclusion	IP, STREP, CA, SSA	50/50	29
2.5.12	TIC pour la gestion des risques environnementaux	IP, STREP, CA, SSA	60/40	40
2.3.4	FET - initiative proactive (xi) Simulation de propriétés émergentes dans les systèmes complexes	STREP	0/100	9

Priorité 3– NMP

3	Nanotechnologies, Matériaux, Procédés de production (NMP)			
FP6-2004-NMP-NI-4	08/12/2004	17/03/2005 (1e ét)	150 M€	IP
FP6-2004-NMP-TI-4	08/12/2004	15/09/2005	120 M€	STREP, CA, SSA
FP6-2004-NMP-SME-4	08/12/2004	17/03/2005 (1e ét)	100 M€	IP-PME

Recherche interdisciplinaire à long terme sur la compréhension des phénomènes, la maîtrise des processus et la mise au point d'outils de recherche	
3.4.1.1-1 Vers des technologies «convergentes»	**STREP**
3.4.1.1-2 Normalisation dans le domaine des nanotechnologies	**SSA**
Nanobiotechnologies	
3.4.1.2-1 Utilisation de la nature comme modèle pour l'élaboration de procédés nouveaux basés sur les nanotechnologies	**STREP**
Techniques d'ingénierie à l'échelle du nanomètre pour la création de matériaux et de composants	
3.4.1.3-1 Nanostructures tridimensionnelles basées sur d'autres éléments que le carbone	**STREP**
Applications dans des domaines tels que la santé et les systèmes médicaux, la chimie, l'optique, l'alimentation et l'environnement	
3.4.1.5-2 Interaction des nanoparticules artificielles avec l'environnement et le monde vivant	**STREP**

Développement de connaissances fondamentales	
3.4.2.1-1 Phénomènes des interfaces dans les matériaux	**STREP**
3.4.2.1-2 Nouvelle génération d'outils de caractérisation avancée des matériaux	**STREP**
3.4.2.1-3 Méthodes de modélisation informatique de matériaux multifonctionnels	**CA**
Technologies associées à la production, à la transformation et au traitement de matériaux multifonctionnels basés sur la connaissance	
3.4.2.2-1 Traitement avancé des matériaux	**CA**
3.4.2.2-3 Films fins multifonctionnels en céramique dotés de propriétés radicalement nouvelles	**STREP**
Ingénierie à l'appui du développement des matériaux	
3.4.2.3-1 Matériaux obtenus par optimisation de la conception : matériaux organiques multifonctionnels	**STREP**
3.4.2.3-2 Matériaux pour l'ionique des solides	**STREP**

Mise au point de nouveaux procédés et de systèmes de fabrication flexibles et intelligents	
3.4.3.1-3 Nouveaux concepts de livraison mondiale	**STREP**
3.4.3.1-4 «Feuille de route» et études prospectives concernant l'avenir des activités de fabrication (Manu*future*)	**SSA**
3.4.3.1-5 Coordination des activités de recherche européennes dans le domaine de la fabrication	**CA**

3.4.5.1 Recherche sur les matériaux de base et les procédés industriels visant la mise au point de matériaux fonctionnels pour les piles à combustible	**STREP**
3.4.5.2 Systèmes améliorés et énergétiquement rationnels de stockage de l'hydrogène, en particulier pour les transports	**STREP**
3.4.5.3 Coopération avec les pays tiers dans le domaine des nanotechnologies, des matériaux multifonctionnels avancés, et de la recherche sur les nouveaux modes de production	**SSA**

Priorité 4– AERONAUTIQUE ET ESPACE

4	Aéronautique et Espace (AEROSPACE)			
FP6-2005-AERO-1	12/03/2005	13/07/2005	230 M€	IP ; NOE ; STREP ; CA
FP6-2005-SPACE-1	12/03/2005	13/07/2005	50 M€	IP ; STREP ; CA ; SSA
FP6-2005-TREN-4_aero	Juin 2005	Déc 2005	? M€	n.d

Priorité 5 – QUALITE ET SURETE ALIMENTAIRES

5	Qualité et sûreté alimentaire (FOOD)			
FP6-2004-Food-3-C	24/07/2004	07/09/2005	5 M€	SSA
FP6-2005-Food-4	Juin 2005	10/2005 (IP/NOE) 01/2006 (STREP /CA /SSA)	130 M€	IP ; NOE ; STREP ; CA ; SSA

Area: Total food chain

- **Improving the quality of pork and pork products for the consumer (IP)**
- **Improving the safety of beef and beef products for the consumer in production and processing (IP)**

Area: Epidemiology of food-related diseases and allergies

- **Nutrient status and requirements of specific population groups (NoE)**
- **Influence of dietary history on coeliac disease (STREP)**

Area: Impact of food on health

- **Milk and dairy products with optimised bioactivity (IP)**
- **Food components reducing the risk of dental diseases (STREP)**
- **Optimising food processing for nutritional and environmental quality (STREP)**

Area: Traceability processes along the production chain

- **Origin and development of unintended micro-organisms in the food and feed chains (IP)**
- **Emerging technologies for food/feed traceability including monitoring**
- **the manufacturing and handling practices in the total chain (IP)**

Area: Methods of analysis, detection and control

- **Quality and safety control strategies for food (NoE)**
- **Developing improved TSE inactivation methods (STREP)**
- ***[A topic on TSE in goats (STREP)]***

Area: Safer and environmentally friendly production methods and technologies and healthier food stuffs

- **Reducing the use of plant protection products (NoE)**
- **Management of waste from farms and fisheries (CA)**
- **Linking national research communities working on *E. coli* O157 research (CA)**

- **High throughput analysis of plant composition and metabolism (STREP)**
- **Reduced fertiliser inputs through improved management of soil microbes (STREP)**
- **Disease risk from alternative and enriched cage systems (STREP)**

Area: Impact of animal feed on human health

- **Feed safety control (STREP)**

Area: Environmental health risks

- **Investigating the cause of allergy (IP)**
- **Investigation of potential health impacts of long-term exposure to disinfection by-products in drinking water (STREP)**
- **Pathogens in drinking water sources (STREP)**

+ Specific Support Actions

Priorité 6.1 – SYSTEMES ENERGETIQUES DURABLES

6.1	Systèmes énergétiques durables			
FP6-2005-TREN-4_energy	Juin 2005	Déc 2005	? M€	n.d

Priorité 6.2 – TRANSPORTS DE SURFACE DURABLES

6.2	Transports de surface durable			
FP6-2002-Transport-2	17/12/2002	Open call	5 M€	SSA
FP6-2005-Transport-4	12/03/2005	01/09/2005	150 M€	IP ; NOE ; STREP ; CA
FP6-2005-TREN-4_transp	Juin 2005	Déc 2005	? M€	n.d

Area	Topic	Instrument
Objective 1 “New technologies and concepts for all surface transport modes (road, rail and waterborne)”	Low cost power-integrated advanced hybrid configurations	IP
	Towards advanced road transport for urban environment	IP
	Efficient rail traction and sustainable energy supply	IP
	Research domain: 1.4: propulsion and power system (for all transport modes and for road transport with emphasis on after-treatment) 1.8: safe and clean supply and delivery of alternative and renewable fuel at distribution point	STREP
	Research domains 1.4 to 1.10 (CF WP)	CA

Objective 2 “Advanced design and production techniques”	Future road vehicle production structures (the 5 day car initiative)	IP
	Development of cost-effective high performance track infrastructure for heavy and light rail systems	IP
	Structuring the European Marine Testing capacity for increased competitiveness	NoE
	Research domain 2.2 (only for a new generation of products and systems in waterborne transport), research domain 2.3 (for all types of transport vehicles and vessels excluding passenger cars), research domain 2.4 and research domain 2.6 (with special consideration of the needs of New Member States)	STREP
	Research domains 2.1 to 2.7	CA

Objective 3 “Re-balancing and integrating different transport modes”	Effective operations in ports	IP
	Research domain 3.14 (only for rail transport) and research domain 3.16	STREP
	Research domains 3.14 to 3.17	CA
Objective 4 “Increasing road, rail and waterborne safety and avoiding traffic congestion”	Safe maritime operations	IP
	Research domain 4.13 (only for powered two-wheelers) and research domains 4.15 and 4.16	STREP
	Research domains 4.11 to 4.16	CA

Priorité 6.3 – CHANGEMENT GLOBAL ET ECOSYSTEMES

6.3	Changement global et écosystème			
FP6-2005-GLOBAL-4	Juin 2005	Nov. 2005		IP ; NOE ; STREP ; CA ; SSA

Priorité 7 – CITOYENS ET GOUVERNANCE

7	Citoyens et gouvernance dans une société de la connaissance				
FP6-2004-CITIZENS-4	08/12/2004	13/04/2005	60 M€	prog. de travail	IP ; NOE
FP6-2004-CITIZENS-5	08/12/2004	13/04/2005	52 M€	prog. de travail	STREP ; CA
FP6-2004-CITIZENS-6	08/12/2004	13/04/2005	4 M€	prog. de travail	SSA

Priorité 18 – EURATOM

18	EURATOM			
Euratom Call Open amendement du 01/12/2004	17/12/2003	12/04/2005 11/04/2005 11/10/2005 11/04/2006	1.5 M€	training fellowship&grants third countries ; SSA ; Transnational access
FP6-2005-EURATOM	Avril 2005	Oct. 2005	52 M€	IP ; NOE ; I3 ; STREP ; CA

Gestion des déchets radioactifs

Sous-priorité	Thème de recherche	Type d'instrument	Budget prévisionnel (en Meuros)
Stockage géologique	Performance assessment techniques to guide the development of the safety case	Projet Intégré (IP)	**Approx. 25 Meuros (Stockage + S&T + Infrastructures)**
	Safety of disposal of spent nuclear fuel and long-lived radioactive waste	STREP ou Action de Coordination	
	Issues related to the governance of spent nuclear fuel and long-lived radioactive waste	STREP ou Action de Coordination	
	Co-ordination of research, development and demonstration (RD&D) priorities and strategies for geological disposal	Action de Coordination	

Gestion des déchets radioactifs

Sous-priorité	Thème de recherche	Type d'instrument	Budget prévisionnel (en Meuros)
Séparation & Transmutation	Nuclear Waste Transmutation in critical reactors	STREP	**Approx. 25 Meuros (Stockage + S&T + Infrastructures)**
	Innovative fuels for waste minimisation in light water reactors	STREP	
	A strategic road-map for unified research in the EU with a view to establishing a true European Research Area in partitioning and transmutation	CA	
	Durable networking of nuclear data research community across Europe and an assessment of future needs of nuclear data for transmutation and other reactors	CA	
Infrastructur	Radioactive Waste Management	I3	

Radioprotection

Sous-priorité	Thème de recherche	Type d'instrument	Budget prévisionnel
Quantification des risques associés à des expositions prolongées à des doses faibles	Cellular and molecular biology research on the effects of low and protracted doses	STREP	**Approx. 14 Meuros**
Expositions médicales et sources naturelles de rayonnements	Safety and efficacy of diagnostic imaging techniques used in nuclear medicine	CA	
Protection de l'Environnement et Radioécologie	Assessment and management of the impact of radio-nuclides on man and the environment	CA	
	An evaluation of the practicability and relative merits of different approaches to protection of the environment from radiation	CA	
Gestion des risques et des urgences	Risk Governance	STREP	
	Emergency Management	STREP	
Protection du lieu de travail	-	-	

Autres Activités …

Sous-priorité	Thème de recherche	Type d'instrument	Budget prévisionnel (en Meuros)
Concepts innovants	Advanced Innovative Reactor Systems	STREP	**Approx. 13**
	Back-end of the Gas Cooled Reactor fuel cycle	STREP	
Enseignement & Formation	Harmonisation of nuclear education and training schemes across EU	CA	
Sûreté des installations nucléaires existantes	Sustainable integration of European research in residual lifetime prediction methodologies	NOE	
	Advanced tools for nuclear safety assessment and component design	STREP CA	
"Cross-cutting activities" dans Autres Activités …	Development of Nuclear Technologies and Safety Infrastructures	I3	
	Platform for nuclear technologies and safety	CA	

pour plus d’information :

Mathieu DOUSSINEAU

01 55 35 25 70

mél: doussineau@anrt.asso.fr